Biovitrum AB

Biovitrum (STO:BVT) The Biovitrum AB (publ) 2008 year-end report reporting date has been changed. The report will be published Tuesday February 10, 2009.

Biovitrum (STO:BVT) Stockholm, January 22 2009. Biovitrum AB (publ) (STO: BVT) today announced the initiation of a process aiming to spin out its small molecule UK based R&D subsidiary Cambridge Biotechnology (CBT) and a range of primary care projects. The proposed transaction reflects Biovitrum's previously announced decision to focus its in-house R&D on specialist pharmaceuticals and protein therapeutics. Biovitrum has engaged Nomura Code in this process.

Biovitrum (STO:BVT) Biovitrum's CEO Martin Nicklasson will give a company presentation at the 27th Annual J.P. Morgan Healthcare Conference being held January 12-15, 2009, in San Francisco, USA.

Biovitrum (STO:BVT) The Annual General Meeting of Biovitrum resolved on 24 April 2008 to issue 284,000 series C shares to secure that the company can fulfill its commitment according to the performance based, long-term share program for 2008 ("Share Program 2008"). Furthermore, the Annual General Meeting resolved to authorize the board of directors to repurchase all issued series C shares for a price per share corresponding to the quota value of the Biovitrum share, i.e. in total SEK 156,000. The series C shares will thereafter be converted to common shares in the number that is required to secure delivery under the Share Program 2008.

Biovitrum (STO:BVT) In accordance with Biovitrum stock option program 2006:3 TO4 2006/2008, 30 642 new shares have been issued at the price SEK 59.00 per share, resulting in Biovitrum being provided funds of a total of SEK 1 807 878.00.

Biovitrum (STO:BVT) Biovitrum to be Global Marketer for Kineret®, Kepivance® and Stemgen®

Biovitrum AB (STO:BVT) Stockholm, Sweden and Waltham, MA - November 24, 2008. Biovitrum AB (publ) (STO:BVT) and Syntonix Pharmaceuticals, Inc., a subsidiary of Biogen Idec (NASDAQ: BIIB) today announced that the company's FIXFc compound for the control and prevention of hemorrhagic episodes in patients with hemophilia B has received an orphan-drug designation from the US Food and Drug Administration (FDA). The FIXFc compound is a recombinant protein in early-stage development for the treatment of hemophilia B, a hereditary bleeding disorder characterized by impaired production of factor IX and the blood's inability to coagulate. The Fc fusion with factor IX is intended to prolong the effect of the compound, the goal being that patients will need less frequent prophylactic treatments than currently existing therapies, which require two to four administrations per week.

Biovitrum AB (STO:BVT) STOCKHOLM, Sweden and COPENHAGEN, Denmark - November 20, 2008. Biovitrum AB (publ) (STO:BVT) and Symphogen A/S have completed the first part of a clinical proof of mechanism study of the recombinant human polyclonal antibody product Sym001 for future prevention of Hemolytic Disease of the Newborn (HDN) that can occur in RhD-negative mothers carrying a RhD-positive fetus. This can lead to an immune reaction causing destruction of the red blood cells in the newborn, which may give rise to severe anemia, jaundice, and even cause heart failure and fatality.

Biovitrum AB (STO:BVT) STOCKHOLM, Sweden and MADISON, New Jersey, USA - November 12, 2008. Biovitrum AB (publ) (STO:BVT) and Wyeth (NYSE:WYE) today announced an extension of the ReFacto® supply agreement until December 31, 2015. Biovitrum will continue to be the sole producer of drug substance for Wyeth for ReFacto®, as well as Xyntha®/ReFacto® AF, the successor products, and will continue to receive royalties from Wyeth's global sales. Biovitrum's co-promotion rights in the Nordic region remain unchanged.

Biovitrum AB (STO:BVT) Strong financial third quarter. Product acquisition from Amgen paves the way to expanded market platform